CHENGHAI CITY CHENGCHENG YONGFA ART CRAFTS FTYBusiness Directories,Company Directories

Company Name: Corporate Name:	CHENGHAI CITY CHENGCHENG YONGFA ART CRAFTS FTY
Company Title:
Company Description:
Keywords to Search:
Company Address:	Chenghai County, Guangdong,,,China
ZIP Code: Postal Code:	515800
Telephone Number:	5717117
Fax Number:
Website:
Email:
Industrial Classification:	Art, Antiques and Collectables -- Crafts
Number of Employees:
Sales Amount:
Credit History: Credit Report:
Contact Person:
Remove my name

Company Directories & Business Directories

copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)

Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Previous company profile:
HECHUAN CITY FULI FACTORY
QUANZHOU CITY DISTRICT HUAFA ART CRAFTS FTY
DONGGUAN JIAHUA ART & CRAFTS CO LTD

Next company profile:
SHANGHAI ART GOODS ENGRAVING FACTORY
SHUNYI COUNTY TIANZHU FULI ART & CRAFT PRODUCT FTY
SHANXI PROVINCE PUXIAN ART & CRAFTS FTY

Company News:

Frontiers | Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs . . .
In fact, IL-5 exerts selective action on eosinophils, which, in turn, sustain airway inflammation and worsen asthma symptoms and control
Anti-interleukin-5 therapy for severe asthma: A new therapeutic option
The new anti-IL-5 therapy agents have now helped to improve asthma care for many patients with severe eosinophilic asthma The 2018 Global Initiative for Asthma (GINA) guideline recommends these therapies for severe asthma despite optimal inhaler therapy
What are the therapeutic applications for IL-5 inhibitors?
Monoclonal antibodies such as mepolizumab and reslizumab are engineered to bind circulating IL-5, thereby preventing its interaction with the IL-5 receptor alpha (IL-5Rα) on eosinophils
Targeting the IL-5 pathway in eosinophilic asthma: a comparison of . . .
Both mepolizumab and benralizumab are subcutaneously administered monoclonal antibodies that target the IL-5 pathway, albeit through different mechanisms of action
Interleukin-5 Antagonists - GlobalRPH
Mepolizumab binds to IL-5 with a dissociation constant of 100 pM, inhibiting the bioactivity of IL-5 by blocking its binding to the alpha chain of the IL-5 receptor complex expressed on the eosinophil cell surface Inflammation is an important component in the pathogenesis of asthma
SEA Eosinophils MOA | NUCALA (mepolizumab) for HCPs
Mepolizumab binds to IL-5, blocking its binding to the alpha chain of the IL-5 receptor complex This inhibits IL-5 signaling, reducing the production and survival of eosinophils
Chapter 4: Anti-IL-5 Therapy and Other Biologics in Severe Asthma - The . . .
Differences in anti-IL-5 therapies, including their mechanism, may be clinically relevant and contribute to a more thorough understanding of how these therapies control airway inflammation
Pathophysiology and Potential Clinical Significance of Il-5: A Review . . .
Interleukin-5 (IL-5) is a critical cytokine that primarily drives the development and differentiation of eosinophils and B cells, playing a key role in the allergic response and the pathogenesis of asthma
Anti-IL-5 biologics carve out severe-asthma niche - Nature
IL-5 inhibitors such as Bosatria and Cinquil stop the cytokine docking to the alpha chain of the IL-5 receptor complex on the surface of eosinophils and their precursor cells; benralizumab,
Frontiers | Targeting the Interleukin-5 Pathway for Treatment of . . .
Mepolizumab and reslizumab, both anti-IL-5 antibodies, bind to and neutralize soluble IL-5, thereby interfering with its ligation to IL-5Rα Benralizumab is directed against the membrane-expressed IL-5Rα chain, and thereby recognizes (and binds) eosinophils directly